AstraZeneca UK Limited
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge, CB2 0AA
United Kingdom
T: +44 (0) 20 3749 5000

astrazeneca.com

October 26, 2016

Dear SOLO2 Steering Committee,

Re: SOLO2 (Study code: D0816C00002)

A phase III randomized, double-blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy

Thank you on behalf of AstraZeneca and ENGOT for your full participation as Steering Committee members. We wanted to ensure that you are among the first to be aware of the content of the press release issued by AstraZeneca this morning regarding the positive outcome of the primary progression free survival (PFS) analysis of the SOLO2 study. The press release is attached.

AstraZeneca has announced that the SOLO2 study has met the primary endpoint demonstrating that progression free survival for olaparib maintenance monotherapy is significantly longer compared to placebo in patients with BRCA mutated relapsed ovarian cancer who are in complete or partial response following platinum based chemotherapy. Initial findings show the safety profile with Lynparza tablets was consistent with previous studies.

An evaluation of the full data is ongoing and the results will be submitted for presentation at a scientific congress in due course. The high level results will be shared with you as steering committee members, in confidence, you will shortly receive an invite for this meeting.

Information for patients participating in SOLO2
As the study is ongoing, treatment allocation will remain blinded to investigators and patients, including those who have discontinued study treatment and are in survival follow up. A further analysis for survival is protocolled which is important to understand the possible long term benefits of olaparib.

Patients still receiving study treatment will continue to be supplied with blinded study treatment for as long as, in your opinion as an investigator, they continue to receive clinical benefit. Assessments for all patients should continue as defined in the study protocol.

We would like take this opportunity to thank you, your staff and patients for your support to date in reaching this important milestone for the SOLO2 study and for your ongoing participation in this study and commitment to the olaparib development programme.

AstraZeneca UK Limited is a subsidiary of AstraZeneca PLC
Registered in England No. 3674842
Registered office: 1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge, CB2 0AA
United Kingdom

If you have any questions about the management of this study please contact your AstraZeneca study monitor, or use the central mailbox email address olaparib@astrazeneca.com. For specific patient-related questions, the study physician Elizabeth Lowe can be contacted on elizabeth.lowe@astrazeneca.com.

Yours sincerely,

Prof Eric Pujade-Lauraine
GINECO-ENGOT
SOLO2 Principal Investigator

Dr. Elizabeth Lowe
AstraZeneca
SOLO2 Study Physician